Background Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized
patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of …

Background Data on thrombosis and current real-world management strategies for
anticoagulation therapy are scarce but important for understanding current issues and …

Coronavirus disease 2019 (COVID-19) is associated with increases in abnormal
coagulation, and particularly D-dimer (DD) levels. Heparin therapy has been recommended …

Background Cardiovascular complications, including myocardial infarction, ischemic stroke,
and pulmonary embolism, represent an important source of adverse outcomes in …

Objective To evaluate the rate of thrombosis, bleeding and mortality comparing
anticoagulant doses in critically ill COVID-19 patients. Design Retrospective observational …

Background This study aims to examine risk factors and complications associated with
bleeding events in patients with COVID-19 who are on anticoagulation. Material and …

A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with
CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial role of …

Background The average frequency of thrombosis in patients with COVID-19 is still high
despite low molecular weight heparin (LMWH) prophylactic. Global hemostasis assays …

Background Few data are available on the rate and characteristics of thromboembolic
complications in hospitalized patients with COVID-19. Methods We studied consecutive …

Background Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some
patients experience cardiovascular complications, including thromboembolic events and …